We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
How well and how safely a new once-weekly self-injected exenatide works compared to twice-daily exenatide in type 2 diabetes
AI simplified
Abstract
In a study of 375 patients with type 2 diabetes, exenatide QWS-AI reduced HbA1c by -1.4% compared to -1.0% with exenatide BID.
- Exenatide QWS-AI resulted in a statistically significant greater reduction in HbA1c than exenatide BID (least-squares mean difference, -0.37%; P = .0072).
- A higher percentage of patients achieved HbA1c levels below 7.0% with exenatide QWS-AI (49.3%) compared to exenatide BID (43.2%), although this difference was not statistically significant (P = .225).
- Both treatment groups experienced weight loss, but the difference in weight reduction between the groups was not significant (P = .37).
- Gastrointestinal adverse events occurred in 22.7% of patients using exenatide QWS-AI, compared to 35.6% in the exenatide BID group.
- Fewer patients in the exenatide QWS-AI group withdrew from the study due to adverse events compared to the exenatide BID group.
- Minor hypoglycaemia was more common among patients using sulfonylureas in conjunction with either treatment.
AI simplified
Key numbers
-1.4%
HbA1c Reduction
Change in HbA1c after 28 weeks for exenatide QWS-AI
22.7%
Gastrointestinal Adverse Events
Proportion of patients with gastrointestinal AEs for exenatide QWS-AI
49.3%
HbA1c <7.0%
Proportion of patients achieving HbA1c <7.0% with exenatide QWS-AI